lisinopril hexal lisinopril 10mg tablet blister pack
medis pharma pty ltd - lisinopril dihydrate, quantity: 11.11 mg (equivalent: lisinopril, qty 10 mg) - tablet, uncoated - excipient ingredients: mannitol; calcium hydrogen phosphate dihydrate; pregelatinised maize starch; croscarmellose sodium; magnesium stearate; iron oxide red; iron oxide black; iron oxide yellow - hypertension: lisinopril hexal is indicated in the treatment of mild to moderate essential hypertension. it may be used alone or concomitantly with other classes of antihypertensive agents. sufficient data have not been provided to support the use of lisinopril in severe hypertension or renovascular hypertension. congestive heart failure: lisinopril hexal is also indicated in the treatment of heart failure. in such patients, it is recommended that lisinopril hexal be administered together with a diuretic. acute myocardial infarction: lisinopril hexal is indicated for the treatment of acute myocardial infarction in haemodynamically stable patients, defined as patients who are not in cardiogenic shock and who have a systolic blood pressure greater than 100 mmhg. lisinopril hexal may be initiated within 24 hours of an acute myocardial infarction.
lisinopril hexal lisinopril 5mg tablet blister pack
medis pharma pty ltd - lisinopril dihydrate, quantity: 5.56 mg (equivalent: lisinopril, qty 5 mg) - tablet, uncoated - excipient ingredients: mannitol; calcium hydrogen phosphate dihydrate; pregelatinised maize starch; croscarmellose sodium; magnesium stearate - hypertension: lisinopril hexal is indicated in the treatment of mild to moderate essential hypertension. it may be used alone or concomitantly with other classes of antihypertensive agents. sufficient data have not been provided to support the use of lisinopril in severe hypertension or renovascular hypertension. congestive heart failure: lisinopril hexal is also indicated in the treatment of heart failure. in such patients, it is recommended that lisinopril hexal be administered together with a diuretic. acute myocardial infarction: lisinopril hexal is indicated for the treatment of acute myocardial infarction in haemodynamically stable patients, defined as patients who are not in cardiogenic shock and who have a systolic blood pressure greater than 100 mmhg. lisinopril hexal may be initiated within 24 hours of an acute myocardial infarction.
lisinopril eg 5 mg tabl.
eg sa-nv - lisinopril dihydrate 5,44 mg - eq. lisinopril 5 mg - tablet - 5 mg - lisinopril dihydrate 5.44 mg - lisinopril
lisinopril eg 20 mg tabl.
eg sa-nv - lisinopril dihydrate 21,78 mg - eq. lisinopril 20 mg - tablet - 20 mg - lisinopril dihydrate 21.78 mg - lisinopril
lisinopril taw pharma 1 mg/ml or. sol.
taw pharma (ireland) ltd. - lisinopril dihydrate 1,088 mg/ml - eq. lisinopril 1 mg/ml - oral solution - 1 mg/ml - lisinopril dihydrate 1.088 mg/ml - lisinopril
lisinopril viatris 20 mg tabl.
viatris gx bv-srl - lisinopril dihydrate 21,77 mg - eq. lisinopril 20 mg - tablet - 20 mg - lisinopril dihydrate 21.77 mg - lisinopril
lisinopril viatris 5 mg tabl.
viatris gx bv-srl - lisinopril dihydrate 5,44 mg - eq. lisinopril 5 mg - tablet - 5 mg - lisinopril dihydrate 5.44 mg - lisinopril
lisinopril teva 20 mg tabl.
teva pharma belgium sa-nv - lisinopril dihydrate 21,84 mg - eq. lisinopril 20 mg - tablet - 20 mg - lisinopril dihydrate 21.84 mg - lisinopril
lisinopril teva 5 mg tabl.
teva pharma belgium sa-nv - lisinopril dihydrate 5,46 mg - eq. lisinopril 5 mg - tablet - 5 mg - lisinopril dihydrate 5.46 mg - lisinopril
lisinopril eg 20 mg tablet
pi pharma - lisinopril dihydrate - tablet - 20 mg - lisinopril dihydrate 21.78 mg - lisinopril